Com uma quantidade significativa de pó seco, as empresas de private equity podem influenciar a pesquisa e onde as terapias são implantadas - e com que rapidez, diz Bob Lavoie, da BCG.
Education
- MBA, Rotman School of Business, University of Toronto
Honors and Awards
- Board of Directors, The Parent-Child Home Program
Bob Lavoie is a core member of the Health Care and Principal Investors & Private Equity practices at Boston Consulting Group, where he Concentra -se em Medtech, Diagnósticos e Ferramentas. Bob aconselha os clientes há mais de 18 anos em questões estratégicas, comerciais, de modelos de negócios e de suporte à transação. Bob está comprometido em fornecer resultados pragmáticos e de criação de valor para seus clientes. Ele trabalhou com clientes em todas as principais áreas de foco terapêuticas, incluindo, entre outros, vasculares, ortopedia, oncologia e neurologia. Ele também completou mais de 100 esforços de diligência para investidores estratégicos e financeiros. Ele é um palestrante frequente em conferências do setor e contribui para as publicações do setor sobre os assuntos das tendências da Medtech e da evolução da paisagem do provedor. Configurações
Recently Bob has also focused on helping clients adapt to the changing health care environment that includes consolidation, value-based care, and the shift to solutions.
Bob’s work experience covers the medtech landscape, including procedure-based devices, drug delivery, and diagnostic systems and tools. He has worked with clients across all major therapeutic areas of focus, including but not limited to vascular, orthopedics, oncology, and neurology. He has also completed more than 100 diligence efforts for strategic and financial investors.
Before he joined the firm, Bob was a senior partner and managing director leading L.E.K.’s New York office and global medtech practice. He is a frequent speaker at industry conferences and contributor to industry publications on the subjects of medtech trends and provider landscape evolution.
